People · Operator
Named in public records as an officer, director or promoter · active 2022–2026 · Biotech / Pharma, AI / ML, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Colossal Biosciences Inc. | — | Biotech / Pharma | Series D+ | $162.6M | $2.8B | 2023 |
| Astromech AI Corp. | — | AI / ML | Series B | $40.5M | $43.9M | 2025 |
| Form Bio Inc. | — | Biotechnology | Series B | $16.0M | $247.3M | 2022 |
| Project Samri Inc. | — | Biotechnology | Series A | $10.5M | $76.5M | 2023 |
Benjamin Lamm at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Benjamin Lamm on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kent Wakeford | 2 | 3 |
| Brian Beard | 2 | 2 |
| James Kim | 1 | 10 |
| John Spinale | 1 | 6 |
| George Church | 1 | 2 |
| Tom Chi | 1 | 2 |
| Vaskar Gnyawali | 1 | 1 |
| Sukanya Srinivasa Rao Arun Punthambaker | 1 | 1 |
| Andrew Busey | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.